Growth in the infertility treatment market is primarily driven by factors such as the declining fertility rate, rising number of fertility clinics worldwide, technological advancements, and increasing public-private investments, funds, and grants. However, the high procedural costs of assisted reproductive technology procedures in developed markets and unsupportive government regulations for certain infertility treatment options are expected to limit market growth to a certain extent.
The coronavirus pandemic is currently presenting various challenges to clinical healthcare providers and patients across the globe. Logistical issues, managing patients with the disease, prioritizing patients with comorbidities and pre-existing conditions, and protecting public & hospital frontline workers from exposure to the COVID-19 infection are the major challenges faced by healthcare systems across the globe.
During the COVID-19 pandemic, a 90% drop was observed in the number of people undergoing IVF cycles. The spread of COVID-19 has not only impacted fertility clinics owing to the cancellation of IVF treatments but has also impacted fertility decisions among couples who were opting for IVF treatment before the pandemic.
For More Information, Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=43497112
Global fertility rates are projected to decline to 2.4 children per woman by 2030 and 2.2 children per woman by 2050. This declining fertility rate has led to a significant increase in the demand for infertility treatment products that determine the fertility window in males and females.
Along with fertility surgeries, thousands of cycles of ART procedures such as in vitro fertilization (IVF) are performed every year globally. The cost of IVF treatment varies from country to country due to the lack of reimbursement policies. A lack of insurance coverage and the poor reimbursement scenario in some parts of the world are limiting the growth of this market.
To leverage the significant growth opportunities in emerging countries, players are increasingly focusing on undertaking strategic developments agreements/partnerships with regional/domestic players, geographical expansions, and acquisitions.to increase their presence in these markets and tap a large number of customers.
Assisted reproductive technology (ART) involves procedures that require the handling of the human egg and embryos. Since the inception of ART procedures, there have been various ethical, legal, and societal controversies regarding the safe administration of gonadotropins, transparency of pregnancy data from clinics, and addressing economic barriers to ART access. Issues related to embryos and what to do with unused embryos are one of the major concerns related to the ART procedure.
The high growth in this owes to the technological advancements and presence of well-established players with strong product portfolio. Along with this growing focus of players towards base expansion through adopting various strategies such as new equipment launch, showcase across the globe is likely to contribute towards the growth of the segment.
The decreasing rates of fertility among females, the growing availability of various fertility treatment options, and the increasing number of fertility centers across the globe are driving the growth of the female infertility treatment market.
